Rhythm Pharmaceuticals Taps Veteran Drug Developer as Chief Medical Officer
Event summary
- Manher (AJ) Joshi, M.D., appointed Chief Medical Officer of Rhythm Pharmaceuticals effective August 17, 2026.
- Joshi brings over two decades of experience in drug development, including roles at Soleno Therapeutics, Neurona Therapeutics, and Atara Biotherapeutics.
- Rhythm Pharmaceuticals focuses on rare neuroendocrine diseases, with its lead asset IMCIVREE (setmelanotide) approved for multiple obesity-related indications.
- Joshi's appointment aligns with Rhythm's expansion into late-stage development of next-generation MC4R agonists.
The big picture
Rhythm Pharmaceuticals' appointment of Manher (AJ) Joshi as Chief Medical Officer underscores its strategic push into late-stage drug development. With a focus on rare neuroendocrine diseases, the company aims to expand its leadership in the MC4R pathway, leveraging Joshi's extensive experience in clinical trials and regulatory processes. This move comes as Rhythm seeks to broaden the reach of its approved drug IMCIVREE and advance its pipeline of investigational therapies.
What we're watching
- Pipeline Progression
- How the pace of late-stage development for next-generation MC4R agonists will impact Rhythm's market position.
- Regulatory Strategy
- Whether Rhythm can sustain its leadership in rare neuroendocrine diseases through global regulatory approvals.
- Commercial Expansion
- The extent to which Joshi's experience will accelerate the commercial growth of IMCIVREE in new indications.